Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$64.42 USD
+1.22 (1.93%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $64.96 +0.54 (0.84%) 7:32 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
Halozyme Therapeutics (HALO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$59.10 | $71.00 | $49.00 | -6.49% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Halozyme Therapeutics comes to $59.10. The forecasts range from a low of $49.00 to a high of $71.00. The average price target represents a decline of 6.49% from the last closing price of $63.20.
Analyst Price Targets (10)
Broker Rating
Halozyme Therapeutics currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy, representing 70% of all recommendations. A month ago, Strong Buy represented 70%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/HALO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
8/7/2024 | Cowen & Co. | Brendan Smith | Strong Buy | Strong Buy |
8/1/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
6/7/2024 | Piper Sandler | Joseph M Catanzaro | Hold | Hold |
5/8/2024 | Goldman Sachs | Corinne Johnson | Hold | Hold |
5/8/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
4/25/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
2/21/2024 | SVB Securities | David Risinger | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $59.10 |
LT Growth Rate | 28.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | 0.99 |